Hikal Ltd
Hikal Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: order book.
The short version
FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth. - Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings. - Animal Health business targeted to reach Rs. Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop. - EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease. - The Animal Health business is targeted to reach Rs.
From Hikal Ltd's Q1 FY27 earnings-call transcript · updated 28 Aug 2026.
Revenue & Sales Performance
- FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth.
- Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings.
- Animal Health business targeted to reach Rs. 400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion.
- Personal Care segment is a new growth driver, expected to cross Rs. 200 crores revenue in the next three years, with EBITDA margins over 20%.
- Crop Protection business anticipates marginal, mid to high single-digit growth due to subdued pricing and demand pressures.
- Pharma CDMO volumes expected to improve as deferred customer orders are executed in the second half of FY27.
- Post U.S. FDA clearance, revenue ramp-up in pharma anticipated with better margins.
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs. 45 crores capex in Q1 FY27: focused on de-bottlenecking, regulatory upgrades, and building new capacities.
- Over last 4 years, approx. Rs. 900 crores invested in capex: Rs. 300 crores for maintenance CAPEX (~Rs. 75 crores/year across 6 sites).
- Rs. 600 crores invested in growth CAPEX:
- - Rs. 300 crores towards agrochemical manufacturing plant (part-impaired, now being retooled to reduce timelines by 12 months for Pharma/Animal Health portfolio).
- - Rs. 150 crores in dedicated Animal Health manufacturing site (validations completed, revenues started).
- - Rs. 100 crores in multipurpose manufacturing facility in Bangalore (already generating revenues).
- New cGMP pilot plants commissioned improving R&D capabilities.
- Commissioned dedicated multi-purpose manufacturing line at Panoli for Personal Care segment.
- Ongoing investments aimed at flexible manufacturing capacities supporting Pharma, Animal Health, and Crop businesses.
- Strategic partnerships discussions underway with Japanese companies to strengthen Animal Health segment.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has several contracts in process, with 2-3 new contracts expected post U.S. FDA clearance.
- Customer confidence remains strong; no contracts or customers have been lost in the last year despite FDA issues.
- Multiple NCE (New Chemical Entity) campaigns and molecule programs are underway, reflecting a healthy order pipeline.
- Animal Health business has long-term contracts with global innovators and repeat campaign orders.
- Pharma CDMO business is building momentum with expanding customer engagement across North America, Europe, Japan, and emerging markets.
- Discussions on strategic partnerships with Japanese companies are progressing well.
- Pipeline includes around 8-9 molecules at various development stages toward commercialization.
- The company is confident of accelerated revenue growth once FDA remediation is completed, with a stepwise recovery envisaged.
- Overall visibility in orders is improving, with gradual normalization of customer ordering patterns and trade cycles.
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Hikal Ltd Q1 FY27 results?
FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth. - Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings. - Animal Health business targeted to reach Rs. Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop. - EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease. - The Animal Health business is targeted to reach Rs.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a below-average growth signal. The stock trades at a P/E of 62.7 with a market cap of ₹2,658 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Rs.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.